Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Fusion Pharmaceuticals Inc. (FUSN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEET DATA June 30, 2023 December 31, 2022 Cash, cash equivalents and investments $ 226,519 $ 186,635 Total assets 268,286 219,064 Total liabilities 65,325 56,843 Total stockholders' equity 202,961 162,221 FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Collaboration revenue $ 34 $ 570 $ 62 $ 1,155 Operating expenses: Research and development 18,994 12,076 34,871 24,737 General and administrative 7,753 7,781 16,759 16,230 Total operating expenses 26,747 19,857 51,630 40,967 Loss from operations Other income : Interest income 2,495 198 4,416 281 Interest expense Other income , net 80 64 Total other inco..."
06/16/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
06/09/2023 SC 13G/A FEDERATED HERMES, INC. reports a 16.7% stake in FUSION PHARMACEUTICALS, INC.
05/16/2023 SC 13D/A ORBIMED ADVISORS LLC reports a 4.6% stake in Fusion Pharmaceuticals Inc.
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Securities Purchase Agreement, by and among Fusion Pharmaceuticals Inc. and the Investors named therein",
"Registration Rights Agreement, by and among Fusion Pharmaceuticals Inc. and the Investors named therein",
"Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates"
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/24/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/16/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/16/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/16/2023 8-K Quarterly results
Docs: "FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEET DATA December 31, 2022 2021 Cash, cash equivalents and investments $ 186,635 $ 220,782 Total assets 219,064 252,271 Total liabilities 56,843 20,815 Total stockholders' equity 162,221 231,456 FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Collaboration revenue $ 140 $ 594 $ 1,461 $ 1,440 Operating expenses: Research and development 17,607 11,811 58,895 56,357 General and administrative 6,950 6,336 30,600 27,098 Total operating expenses 24,557 18,147 89,495 83,455 Loss from operations Other income: Interest income 1,309 81 2,161 381 Interest expense — — Other income, net 63 469 Total other income, ..."
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/06/2023 SC 13D/A HealthCap VII, L.P. reports a 6.1% stake in Fusion Pharmaceuticals Inc.
02/14/2023 8-K/A Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ...
Docs: "OPTION AND ASSET PURCHASE AGREEMENT dated as of November 14, 2022 by and between RADIOMEDIX, INC. and FUSION PHARMACEUTICALS INC.",
"Investors Registration Rights Agreement Investor Questionnaire",
"REGISTRATION RIGHTS AGREEMENT",
"Fusion Pharmaceuticals to Acquire Phase 2 Program for 225 Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer",
"Investor Presentation",
"Updated Corporate Disclosure"
02/13/2023 8-K Quarterly results
02/09/2023 SC 13G/A FMR LLC reports a 6% stake in FUSION PHARMACEUTICALS INC
02/01/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/27/2023 SC 13G/A JOHNSON & JOHNSON reports a 8.2% stake in Fusion Pharmaceuticals Inc.
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEET DATA September 30, 2022 December 31, 2021 Cash, cash equivalents and investments $ 205,481 $ 220,782 Total assets 238,493 252,271 Total liabilities 55,351 20,815 Total stockholders' equity 183,142 231,456 FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Collaboration revenue $ 166 $ 325 $ 1,321 $ 846 Operating expenses: Research and development 16,551 12,684 41,288 44,546 General and administrative 7,420 7,156 23,650 20,762 Total operating expenses 23,971 19,840 64,938 65,308 Loss from operations Other income: Interest income, net 190 107 220 300 Other income, net 27 406 Total other income..."
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/10/2022 8-K Quarterly results
04/29/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/13/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
04/04/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy